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Veterinarians in clinical practice are quite familiar with the characteristics of inactivated and modified-live 
vaccines intended to help protect dogs and cats against bacterial and viral infectious diseases.  Indeed, generations of 
veterinary students have been required to learn the relative advantages and disadvantages of inactivated (i.e., killed) and 
modified-live (i.e., attenuated) vaccines.   Most of the vaccines currently available for use in dogs and cats can be 
placed into one or other of these two ‘conventional’ categories, although it is perhaps a little unfair to lump them 
together and describe them as conventional, since some are relatively sophisticated (e.g., a modified-live, temperature-
sensitive mutant virus).  Relatively few currently-available canine and feline vaccines are based on recombinant DNA 
technology.   However, it seems likely that—over the next few years—a startling profusion of novel vaccines will be 
marketed for use in cats and dogs.  Most of these will be based on recombinant DNA technology and not all of them 
will be prophylactic; some will most likely be therapeutic. 
Recombinant, attenuated, canarypox virus vectored vaccines against canine distemper, rabies, West Nile virus and 
feline leukaemia virus (FeLV) are already available on the market.  More are sure to follow.  Each of these vaccines 
consists of a live, attenuated canarypox virus that has been genetically engineered to carry one or more genes that 
encode immunogenic proteins of companion animal pathogens. The ‘foreign’, inserted genes are expressed to produce 
immunogenic protein in the recombinant poxvirus.  Poxviruses are large DNA viruses, with large genomes, so a 
substantial amount of foreign genetic material can be inserted into recombinant poxviruses.  After these vaccines are 
administered to mammals, the recombinant canarypox virus is thought not to replicate successfully to completion.  
However the immunogenic proteins of companion animal pathogens are processed in a manner that closely parallels a 
natural infection. Unlike ‘conventional’ modified-live vaccines, canarypox vectored vaccines cannot revert to virulence 
in the recipient dog or cat, since they are essentially an attenuated avian virus.  They are live vaccines and do not need 
to be adjuvanted.  Therefore, it expected that the risk of cats developing injection site sarcomas will be diminished by 
their use.  Transdermal, needle-free delivery of some of these vectored poxvirus vaccines is already being practiced by 
veterinarians in some countries. 
Several other kinds of virus, and indeed bacteria, have been investigated or considered as potential vectors for use 
in companion animal vaccines.  So far, poxviruses have dominated among the licensed veterinary vaccines. 
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Although the use of vectored vaccines for immunization of dogs and cats is certainly innovative and exciting, there 
are other interesting and arguably even more radical approaches to vaccination being investigated.  For example, the use 
of ‘DNA vaccines’ involves the direct introduction of bacterial plasmids (closed circular DNA molecules) that are 
engineered to encode a ‘foreign’ immunogenic protein of a companion animal pathogen (say, a virus).  Once 
‘inoculated’ (e.g., by intramuscular injection or ‘gene gun’), these plasmids are taken up by cells in the vaccine 
recipient (e.g., muscle cells) and are expressed, leading to production of the immunogenic protein.   This can lead to 
substantial humoral and cellular immune responses.  Some ‘naked DNA’ candidate vaccines under investigation consist 
of a mixture of several different plasmids.  Some of these plasmids encode genes for immunogenic proteins of the 
pathogen and others encode immunostimulatory molecules such as interleukins. 
Further in the future, it is possible that some bacteriophages—viruses that infect and kill bacteria—may prove 
useful as vectors for delivery of ‘foreign’ immunogenic proteins and the DNA that encodes them.  Recombinant 
bacteriophages can be grown up in large quantities and their external protein coats protect the recombinant DNA 
genome.   Bacteriophages are reported to be rapidly taken up by antigen presenting cells (APCs), appearing in Kuppfer 
cells in the spleen and liver shortly after injection.   In some early studies, bacteriophage-based vaccines have been 
reported to provoke much stronger immune responses than do equivalent naked DNA vaccines, perhaps because 
bacteriophages protect their enclosed nucleic acid from nuclease attack and target APCs. 
Therapeutic, as opposed to prophylactic, vaccines (e.g., directed against various canine and feline malignancies) are 
likely to appear on the market in the not-too-distant future.  Numerous vaccines of this kind are already undergoing 
clinical trials for use in humans.  As our understanding of the role of viruses in the aetiology of companion animal 
neoplasms grows, it is likely that new vaccines to prevent virally-induced forms of cancer will be introduced.   
Eventually it may prove possible to develop vaccines for prevention of some malignancies that do not have a viral 
aetiology. 
